These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25565272)

  • 1. Polymorphisms of cell cycle control genes influence the development of sporadic medullary thyroid carcinoma.
    Barbieri RB; Bufalo NE; Secolin R; Assumpção LV; Maciel RM; Cerutti JM; Ward LS
    Eur J Endocrinol; 2014 Dec; 171(6):761-7. PubMed ID: 25565272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that polymorphisms in detoxification genes modulate the susceptibility for sporadic medullary thyroid carcinoma.
    Barbieri RB; Bufalo NE; Secolin R; Silva AC; Assumpção LV; Maciel RM; Cerutti JM; Ward LS
    Eur J Endocrinol; 2012 Feb; 166(2):241-5. PubMed ID: 22048975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
    Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
    Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.
    Mishra V; Kowtal P; Rane P; Sarin R
    Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
    Gayther SA; Song H; Ramus SJ; Kjaer SK; Whittemore AS; Quaye L; Tyrer J; Shadforth D; Hogdall E; Hogdall C; Blaeker J; DiCioccio R; McGuire V; Webb PM; Beesley J; Green AC; Whiteman DC; ; Goodman MT; Lurie G; Carney ME; Modugno F; Ness RB; Edwards RP; Moysich KB; Goode EL; Couch FJ; Cunningham JM; Sellers TA; Wu AH; Pike MC; Iversen ES; Marks JR; Garcia-Closas M; Brinton L; Lissowska J; Peplonska B; Easton DF; Jacobs I; Ponder BA; Schildkraut J; Pearce CL; Chenevix-Trench G; Berchuck A; Pharoah PD;
    Cancer Res; 2007 Apr; 67(7):3027-35. PubMed ID: 17409409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.
    Mishra V; Kowtal P; Rane P; Sarin R
    Cancer Med; 2019 Oct; 8(13):6151-6161. PubMed ID: 31408923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma.
    Pasquali D; Circelli L; Faggiano A; Pancione M; Renzullo A; Elisei R; Romei C; Accardo G; Coppola VR; De Palma M; Ferolla P; Grimaldi F; Colao A; Colantuoni V
    Eur J Endocrinol; 2011 Mar; 164(3):397-404. PubMed ID: 21177330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.
    Kibel AS; Suarez BK; Belani J; Oh J; Webster R; Brophy-Ebbers M; Guo C; Catalona WJ; Picus J; Goodfellow PJ
    Cancer Res; 2003 May; 63(9):2033-6. PubMed ID: 12727815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma.
    Nascimento FP; Cardoso MG; Lindsey SC; Kunii IS; Valente FO; Kizys MM; Delcelo R; Camacho CP; Maciel RM; Dias-Da-Silva MR
    Mol Med Rep; 2016 Feb; 13(2):1653-60. PubMed ID: 26718898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.
    Akulevich NM; Saenko VA; Rogounovitch TI; Drozd VM; Lushnikov EF; Ivanov VK; Mitsutake N; Kominami R; Yamashita S
    Endocr Relat Cancer; 2009 Jun; 16(2):491-503. PubMed ID: 19286843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
    El Naofal M; Kim A; Yon HY; Baity M; Ming Z; Bui-Griffith J; Tang Z; Robinson M; Grubbs EG; Cote GJ; Hu P
    Ann Clin Lab Sci; 2017 Sep; 47(5):523-528. PubMed ID: 29066476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide copy number analysis in a family with p.G533C RET mutation and medullary thyroid carcinoma identified regions potentially associated with a higher predisposition to lymph node metastasis.
    Araujo AN; Moraes L; França MI; Hakonarson H; Li J; Pellegrino R; Maciel RM; Cerutti JM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1104-12. PubMed ID: 24601688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic.
    Polakova V; Pardini B; Naccarati A; Landi S; Slyskova J; Novotny J; Vodickova L; Bermejo JL; Hanova M; Smerhovsky Z; Tulupova E; Kumar R; Hemminki K; Vodicka P
    Hum Mutat; 2009 Apr; 30(4):661-8. PubMed ID: 19224585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology.
    Machens A; Dralle H
    Eur J Surg Oncol; 2015 Jun; 41(6):766-72. PubMed ID: 25468749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
    Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
    Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global DNA methylation profile in medullary thyroid cancer patients.
    Ceolin L; Goularte APP; Ferreira CV; Romitti M; Maia AL
    Exp Mol Pathol; 2018 Aug; 105(1):110-114. PubMed ID: 29935954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.